Premium
Methotrexate: An active drug in bladder cancer
Author(s) -
Natale R. B.,
Yagoda A.,
Watson R. C.,
Whitmore W. F.,
Blumenreich M.,
Braun D. W.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810315)47:6<1246::aid-cncr2820470603>3.0.co;2-g
Subject(s) - medicine , mucositis , methotrexate , confidence interval , chemotherapy , urinary system , surgery , cancer , bladder cancer , cisplatin , gastroenterology , urology
Forty‐nine patients with transitional urothelial tract tumors received methotrexate: 0.5–1.0 mg/kg I.V. Q W (40 patients) or 250 mg/M 2 in a 2‐hour infusion with citrovorum factor rescue 24 hours later (nine patients). Eleven (26%, 95% confidence limits 13–39%) of 42 patients with bidimensionally measurable metastases achieved partial remission. Most responses occurred within 2–3 weeks and persisted for a median duration of six months (range, 2–20). Response rates were increased to 38% (6/16 patients, 95% confidence limits 18–65%) in patients who had no prior chemotherapy, and a 90–100% performance status (50,5/10 patients, 95% confidence limits 22–78%) compared with 19% (5/26, 95% confidence limits 8–37%) in patients who had prior chemotherapy and a ≦80% performance status (19%, 6/32 cases, 95% confidence limits 9–32%). Toxicity included mucositis and myelosuppression. A review of the literature coupled with the present data suggest that methotrexate is as active as cisplatin in the treatment of patients with advanced urinary bladder cancer.